Comparing the current results to its competitors, Takeda Pharmaceutical Limited reported Revenue increase in the 4 quarter 2025 by 0.06 % year on year. The revenue growth was below Takeda Pharmaceutical Limited's competitors' average revenue growth of 2.96 %, achieved in the same quarter.
Takeda Pharmaceutical Company Limited Net Income in the 4 quarter 2025 fell year on year by -30.16%, slower than its competitors' income growth of 4179.4 %
Takeda Pharmaceutical Limited's Comment on Competition and Industry Peers
The company operates in a competitive landscape that includes large international firms with capabilities in research and development, manufacturing, and marketing, as well as biopharmaceutical companies specializing in specific therapeutic areas. Competition factors include product safety, efficacy, dosing convenience, reliability, availability, and pricing. The market also faces competition from generic drugs and biosimilars following the expiration of patent protection or regulatory exclusivity. Intellectual property protection, such as patents and regulatory exclusivity periods, is important for maintaining competitive advantage. The company collaborates with Nabla Bio in the U.S. on research involving novel protein sequences using artificial intelligence and experimental technologies for drug design.
With modest revenue growth of 0.06 % within Overall company, Takeda Pharmaceutical Company Limited failed to increase sales with the same pace, like most of company's peers within this division. << More on TAK Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Takeda Pharmaceutical Company Limited
Briacell Therapeutics Corp Share Performance
+3.12%
Over The Past 5 Days
Briacell Therapeutics Corp
Profile
Briacell Therapeutics Corp's business model is centered around the development and commercialization of personalized immunotherapies for the treatment of cancer.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Fortress Biotech Inc operates as a biopharmaceutical company that acquires, develops, and commercializes novel pharmaceutical and biotechnology products. Their business model focuses on partnering with academic institutions and biotech companies to advance preclinical and clinical-stage therapies for various diseases. Additionally, they aim to leverage their expertise and partnerships to improve the development process and bring innovative treatments to patients in need.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Sources:
Takeda Pharmaceutical Company Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Takeda Pharmaceutical Company Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
